Boston Scientific Corporation $BSX Shares Bought by Mufg Securities Americas Inc.

Mufg Securities Americas Inc. grew its position in Boston Scientific Corporation (NYSE:BSX) by 21.9% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 39,957 shares of the medical equipment provider’s stock after acquiring an additional 7,168 shares during the quarter. Mufg Securities Americas Inc.’s holdings in Boston Scientific were worth $3,901,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the company. Baldwin Investment Management LLC raised its stake in Boston Scientific by 5.4% in the 3rd quarter. Baldwin Investment Management LLC now owns 13,145 shares of the medical equipment provider’s stock valued at $1,283,000 after purchasing an additional 675 shares during the last quarter. AXQ Capital LP purchased a new stake in shares of Boston Scientific during the third quarter worth $1,434,000. Compound Planning Inc. raised its position in shares of Boston Scientific by 22.1% in the third quarter. Compound Planning Inc. now owns 13,445 shares of the medical equipment provider’s stock valued at $1,313,000 after buying an additional 2,436 shares during the last quarter. Cary Street Partners Investment Advisory LLC boosted its position in Boston Scientific by 5.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 2,106 shares of the medical equipment provider’s stock worth $206,000 after acquiring an additional 103 shares during the last quarter. Finally, Fortis Capital Management LLC purchased a new stake in Boston Scientific during the 3rd quarter valued at about $5,895,000. 89.07% of the stock is currently owned by hedge funds and other institutional investors.

Boston Scientific Stock Performance

Shares of Boston Scientific stock opened at $74.37 on Tuesday. The business has a 50-day simple moving average of $88.87 and a 200-day simple moving average of $96.32. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.08 and a current ratio of 1.62. Boston Scientific Corporation has a one year low of $72.69 and a one year high of $109.50. The company has a market cap of $110.36 billion, a PE ratio of 38.33, a P/E/G ratio of 1.03 and a beta of 0.67.

Boston Scientific (NYSE:BSX) last issued its earnings results on Wednesday, February 4th. The medical equipment provider reported $0.80 earnings per share for the quarter, beating the consensus estimate of $0.78 by $0.02. Boston Scientific had a net margin of 14.44% and a return on equity of 19.63%. The firm had revenue of $5.29 billion for the quarter, compared to analysts’ expectations of $5.29 billion. During the same quarter last year, the company earned $0.70 earnings per share. The firm’s revenue was up 15.9% compared to the same quarter last year. Boston Scientific has set its Q1 2026 guidance at 0.780-0.800 EPS and its FY 2026 guidance at 3.430-3.490 EPS. On average, equities research analysts forecast that Boston Scientific Corporation will post 2.85 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Arthur C. Butcher sold 17,313 shares of the business’s stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at approximately $2,396,580. The trade was a 42.32% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Michael F. Mahoney sold 160,901 shares of the firm’s stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $93.49, for a total value of $15,042,634.49. Following the completion of the sale, the chief executive officer owned 1,411,735 shares in the company, valued at approximately $131,983,105.15. This represents a 10.23% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders own 0.50% of the company’s stock.

Analyst Upgrades and Downgrades

Several brokerages have recently weighed in on BSX. Wall Street Zen cut Boston Scientific from a “buy” rating to a “hold” rating in a report on Saturday, February 7th. UBS Group dropped their price objective on shares of Boston Scientific from $140.00 to $120.00 and set a “buy” rating for the company in a report on Thursday, February 5th. Citigroup decreased their target price on shares of Boston Scientific from $130.00 to $102.00 and set a “buy” rating on the stock in a report on Thursday, February 5th. Morgan Stanley reduced their price target on shares of Boston Scientific from $130.00 to $118.00 and set an “overweight” rating on the stock in a research report on Thursday, February 5th. Finally, The Goldman Sachs Group set a $99.00 price objective on Boston Scientific in a report on Thursday, February 5th. One analyst has rated the stock with a Strong Buy rating, twenty have issued a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $108.36.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.